Cargando…

End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer

BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institut...

Descripción completa

Detalles Bibliográficos
Autores principales: Narang, Amol K., Trieu, Janson, Radwan, Noura, Ram, Ashwin, Robertson, Scott P., He, Pei, Gergis, Carol, Griffith, Emily, Singh, Harleen, DeWeese, Tate A., Honig, Stephanie, Annadanam, Anvesh, Greco, Stephen, DeVille, Curtiland, McNutt, Todd, DeWeese, Theodore L., Song, Daniel Y., Tran, Phuoc T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429233/
https://www.ncbi.nlm.nih.gov/pubmed/28094250
http://dx.doi.org/10.1038/pcan.2016.67
_version_ 1783235983043461120
author Narang, Amol K.
Trieu, Janson
Radwan, Noura
Ram, Ashwin
Robertson, Scott P.
He, Pei
Gergis, Carol
Griffith, Emily
Singh, Harleen
DeWeese, Tate A.
Honig, Stephanie
Annadanam, Anvesh
Greco, Stephen
DeVille, Curtiland
McNutt, Todd
DeWeese, Theodore L.
Song, Daniel Y.
Tran, Phuoc T.
author_facet Narang, Amol K.
Trieu, Janson
Radwan, Noura
Ram, Ashwin
Robertson, Scott P.
He, Pei
Gergis, Carol
Griffith, Emily
Singh, Harleen
DeWeese, Tate A.
Honig, Stephanie
Annadanam, Anvesh
Greco, Stephen
DeVille, Curtiland
McNutt, Todd
DeWeese, Theodore L.
Song, Daniel Y.
Tran, Phuoc T.
author_sort Narang, Amol K.
collection PubMed
description BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993–2006 and who had an EOR PSA (n=688, median follow-up 11.2 years). We analyzed the association of an end-of-radiation (EOR) prostate-specific antigen (PSA) level, obtained during the last week of radiation, with survival outcomes. Multivariable-adjusted cox proportional hazards models were constructed to assess associations between a detectable EOR PSA (defined as ≥0.1 ng ml(−1)) and biochemical failure-free survival (BFFS), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Kaplan-Meier survival curves were constructed, with stratification by EOR PSA. RESULTS: At the end of radiation, the PSA level was undetectable in 30% of patients. Men with a detectable EOR PSA experienced inferior 10-year BFFS (49.7% vs. 64.4%, p<0.001), 10-year MFS (84.8% vs. 92.0%, p=0.003), 10-year PCSS (94.3% vs. 98.2%, p=0.007), and 10-year OS (75.8% vs. 82.5%, p=0.01), as compared to men with an undetectable EOR PSA. Among NCCN intermediate- and high-risk men who were treated with definitive radiation and androgen deprivation therapy (ADT), a detectable EOR PSA was more strongly associated with PCSS than initial NCCN risk level (EOR PSA: HR 5.89, 95% CI 2.37–14.65, p<0.001; NCCN risk level: HR 2.01, 95% CI 0.74–5.42, p=0.168). Main study limitations are retrospective study design and associated biases. CONCLUSIONS: EOR PSA was significantly associated with survival endpoints in men who received treated with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation.
format Online
Article
Text
id pubmed-5429233
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-54292332017-07-17 End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer Narang, Amol K. Trieu, Janson Radwan, Noura Ram, Ashwin Robertson, Scott P. He, Pei Gergis, Carol Griffith, Emily Singh, Harleen DeWeese, Tate A. Honig, Stephanie Annadanam, Anvesh Greco, Stephen DeVille, Curtiland McNutt, Todd DeWeese, Theodore L. Song, Daniel Y. Tran, Phuoc T. Prostate Cancer Prostatic Dis Article BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993–2006 and who had an EOR PSA (n=688, median follow-up 11.2 years). We analyzed the association of an end-of-radiation (EOR) prostate-specific antigen (PSA) level, obtained during the last week of radiation, with survival outcomes. Multivariable-adjusted cox proportional hazards models were constructed to assess associations between a detectable EOR PSA (defined as ≥0.1 ng ml(−1)) and biochemical failure-free survival (BFFS), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Kaplan-Meier survival curves were constructed, with stratification by EOR PSA. RESULTS: At the end of radiation, the PSA level was undetectable in 30% of patients. Men with a detectable EOR PSA experienced inferior 10-year BFFS (49.7% vs. 64.4%, p<0.001), 10-year MFS (84.8% vs. 92.0%, p=0.003), 10-year PCSS (94.3% vs. 98.2%, p=0.007), and 10-year OS (75.8% vs. 82.5%, p=0.01), as compared to men with an undetectable EOR PSA. Among NCCN intermediate- and high-risk men who were treated with definitive radiation and androgen deprivation therapy (ADT), a detectable EOR PSA was more strongly associated with PCSS than initial NCCN risk level (EOR PSA: HR 5.89, 95% CI 2.37–14.65, p<0.001; NCCN risk level: HR 2.01, 95% CI 0.74–5.42, p=0.168). Main study limitations are retrospective study design and associated biases. CONCLUSIONS: EOR PSA was significantly associated with survival endpoints in men who received treated with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation. 2017-01-17 2017-06 /pmc/articles/PMC5429233/ /pubmed/28094250 http://dx.doi.org/10.1038/pcan.2016.67 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Narang, Amol K.
Trieu, Janson
Radwan, Noura
Ram, Ashwin
Robertson, Scott P.
He, Pei
Gergis, Carol
Griffith, Emily
Singh, Harleen
DeWeese, Tate A.
Honig, Stephanie
Annadanam, Anvesh
Greco, Stephen
DeVille, Curtiland
McNutt, Todd
DeWeese, Theodore L.
Song, Daniel Y.
Tran, Phuoc T.
End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
title End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
title_full End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
title_fullStr End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
title_full_unstemmed End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
title_short End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
title_sort end-of-radiation psa as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429233/
https://www.ncbi.nlm.nih.gov/pubmed/28094250
http://dx.doi.org/10.1038/pcan.2016.67
work_keys_str_mv AT narangamolk endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT trieujanson endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT radwannoura endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT ramashwin endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT robertsonscottp endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT hepei endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT gergiscarol endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT griffithemily endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT singhharleen endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT deweesetatea endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT honigstephanie endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT annadanamanvesh endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT grecostephen endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT devillecurtiland endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT mcnutttodd endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT deweesetheodorel endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT songdaniely endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer
AT tranphuoct endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer